secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001140361-24-012605
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves extended room temperature storage for ADMA's ASCENIV and BIVIGAM
-----------------------------------------------------------------------------

- FDA approved supplemental BLAs to allow 4-week room temperature (25°C) storage at any time during the 36-month shelf life.
- Previously, room temperature storage was only allowed during the first 24 months; now applies to all existing and future lots.
- CEO Adam Grossman stated the approval enables reaching customers previously limited by cold chain constraints.
- Both products are immediately commercially available to U.S. healthcare providers.
- Approval expected to improve inventory management and product administration for providers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124012605/0001140361-24-012605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124012605/ef20023792_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-012605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer